目的 匯總分析2017—2019年天津醫(yī)科大學(xué)朱憲彝紀(jì)念醫(yī)院門診患者降脂藥物的使用情況及發(fā)展趨勢(shì)，為降脂藥的臨床合理應(yīng)用提供科學(xué)依據(jù)。方法 選取2017—2019年天津醫(yī)科大學(xué)朱憲彝紀(jì)念醫(yī)院門診降脂類藥物的相關(guān)數(shù)據(jù)，采用WHO推薦的限定日劑量（DDD）、用藥頻度（DDDs）、日均費(fèi)用（DDC）和排序比（B/A）等對(duì)選定的降脂藥物進(jìn)行統(tǒng)計(jì)分析。結(jié)果 2017—2019年該院降脂藥的銷售額比較穩(wěn)定，呈逐年上升趨勢(shì)。其中他汀類降脂藥銷售額最高，占比最多，連續(xù)3年始終占據(jù)首位，其次是貝特類。具體藥物中阿托伐他?。⑵胀祝┻B續(xù)3年排名第1位；瑞舒伐他汀鈣膠囊2017、2018年基本穩(wěn)定，2019年下降幅度較大；2017—2019年阿托伐他汀的DDDs排名第1位，非諾貝特的DDDs連年上升，且排名第2位；氟伐他汀連續(xù)3年最低。DDC值最高的是普羅布考，最低的是苯扎貝特。2017—2019年大部分藥品的B/A值都在1.00左右，同步率較好。結(jié)論 2017—2019年天津醫(yī)科大學(xué)朱憲彝紀(jì)念醫(yī)院降脂藥物的選擇與使用相對(duì)合理，藥品種類逐漸增多，患者用藥情況符合指南要求，國(guó)家集采政策的實(shí)施，2019年患者的藥品費(fèi)用大幅下降。

Objective To summarize and analyze the utilization and development trend of hypolipidemic drugs in outpatients of A tertiary hospital in Tianjin from 2017 to 2019, in order to provide references for clinical rational drug use. Methods The amount, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of hypolipidemic drugs in A tertiary hospital in Tianjin from 2017 to 2019 were calculated and analyzed statistically. Results From 2017 to 2019, the sales of hypolipidemic drugs were relatively balanced, showing an upward trend year by year. Among them, the sales volume of statins-related drugs is the highest, accounting for the largest proportion, and has always occupied the first place for three consecutive years, followed by the bethe drugs. Among the specific drugs, atorvastatin (Lipitor) ranked the first for three consecutive years. Rosuvastatin calcium capsules were basically stable in 2017 and 2018, and decreased significantly in 2019. From 2017 to 2019, DDDs of atorvastatin ranked first, while fenofibrate increased steadily and ranked second. Fluvastatin was the lowest for three consecutive years. The highest DDC is probucol and the lowest was bezafibrate in 2017—2019. The B/A value of most drugs is about 1.00 and with good synchronicity in 2017—2019. Conclusion The selection and use of antihypertensive drugs for hyperlipidemia patients in A tertiary hospital in Tianjin from 2017 to 2019 are relatively, the types of drugs increased gradually, and the medication situation of patients met the requirements of the guidelines, with the implementation of the national centralized purchase policy, the drug costs of patients will drop significantly in 2019.

R977

天津市科技計(jì)劃項(xiàng)目（20KPHDRC00020）